Home/EyePoint Pharmaceuticals/Ramiro Ribeiro, M.D., Ph.D.
RR

Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Pipeline

DrugIndicationPhase
DURAVYU™ (EYP-1901)Wet Age-Related Macular Degeneration (Wet AMD)Phase 3
EYP-2301Serious Retinal DiseasesPre-clinical